Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?

Key Takeaways TEM jumped 12.5% in early June, fueled by new product launches and strong investor response. The $200M deal with AstraZeneca boosts TEM's role in AI-driven oncology diagnostics and drug discovery. Despite revenue growth and tech advances, TEM remains unprofitable and trades at a premium to peers.Tempus AI (TEM) surged 12.5% in the first week of June, outperforming the broader market and the benchmarks by a wide margin. This rally came largely on the heels of investors’ positive reaction to t ...